A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept 125mg Administered Subcutaneously in Chinese Subjects With Active Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Abatacept (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Simcere Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 01 Jul 2016 Status changed from not yet recruiting to recruiting.
- 12 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Jun 2016.